Aldeyra Therapeutics (ALDX)
(Delayed Data from NSDQ)
$4.93 USD
-0.08 (-1.60%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $4.89 -0.04 (-0.81%) 4:48 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALDX 4.93 -0.08(-1.60%)
Will ALDX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALDX
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
ALDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aldeyra Therapeutics (ALDX) Upgraded to Strong Buy: What Does It Mean for the Stock?
Are Medical Stocks Lagging Amgen (AMGN) This Year?
Is the Options Market Predicting a Spike in Aldeyra Therapeutics (ALDX) Stock?
Other News for ALDX
ALDX forms NR7 on September 19
ALDX forms Lower Bollinger Band Walk on September 18
MACD Bearish Centerline Cross appears for ALDX after 2.55% move
Aldeyra: 2 CRLs And A Precedent Gap Ahead Of Repro's PDUFA Merit Caution (Rating Downgrade)
Is ALDX poised for a decline? Fell Below 50 Day Moving Average shows up after tumbling 5.57%